---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-25-000030"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2025-07-24T23:59:59+00:00"
generated_at: "2026-05-18T02:23:17.308577+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NovoCure Q2 2025 revenue $158.8M (+6% YoY), net loss $40.1M; plans pancreatic cancer PMA in Q3

## Summary
- Net revenues $158.8M, up 6% YoY; net loss $40.1M ($0.36 loss per share); adjusted EBITDA -$9.9M.
- 4,331 active patients on TTFields globally; Optune Gio active patients up 7% YoY.
- Phase 3 PANOVA-3 pancreatic cancer trial met primary endpoint; PMA submission to FDA planned Q3 2025.
- PMA for brain metastases from NSCLC planned H2 2025; TRIDENT and PANOVA-4 readouts expected H1 2026.
- Cash and investments $911.5M as of June 30, 2025.

## SEC filing metadata
- accession: 0001645113-25-000030
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2025-07-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000030/0001645113-25-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000030/nvcr-20250724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-25-000030
- JSON: https://secwatch.observer/filing/0001645113-25-000030.json
- Plain text: https://secwatch.observer/filing/0001645113-25-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.